.png)
.png)
Stablepharma secures Innovate UK grant, bridge funding round to launch
This joint Innovate UK grant will advance the clinical development of Stablepharma’s lead candidate, SPVX02, a fridge-free vaccine for the prevention of Tetanus and Diphtheria, validating its safety and efficacy through first-in-human clinical trials.
Broken String Biosciences closes $15 million Series A funding round
Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, has closed a $15 million Series A investment round.
CPI launches RNA Centre of Excellence
UK's first RNA therapeutic innovation center opens in Darlington, driving cutting-edge vaccine and therapeutic development.
UK rare disease research landscape mapped for first time
A detailed view of rare disease research in the UK has been captured for the first time in a new report published today. It reveals over £1.1 billion has been invested by Government and charities over a five-year-period.
Life Science Group: A finalist for the Innovate UK KTP Awards 2023
Life Science Group (LSG) proudly announces its selection as a finalist in the Impact and Transformation Award category of the esteemed 2023 Innovate UK Knowledge Transfer Partnership (KTP) Best of the Best Awards.
Advancing early lung cancer diagnosis
Life Science Group are delighted to be part of a consortium, led by Welsh scientists at Aberystwyth University, to develop a novel and potentially disruptive lateral flow device for the detection of early-stage lung cancer.
Accelerating innovation in cell culture solutions through collaborative funding
Life Science Group Ltd (LSG) is excited to announce that its joint application with the Mary Lyon Centre (MLC) at MRC Harwell to the MRC National Mouse Genetics Network (NMGN) Business Engagement Fund has been approved in principle, pending the signature of the relevant agreements.
FDA grants US Orphan Drug Designation to Medannex's MDX-124
Medannex Ltd announced today that its novel therapy, MDX-124, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA).
AlveoGene launches to develop inhaled gene therapies for rare respiratory disorders
New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC)
AstraZeneca commits £100 million to advance UK energy efficiency
15-year agreement with Future Biogas will provide 100 GWh of green gas (biomethane) annually, equivalent to meet the heat demands of over 8,000 homes
